|1.||Haller, Hermann: 6 articles (01/2016 - 01/2006)|
|2.||Borghi, Claudio: 5 articles (01/2012 - 05/2003)|
|3.||Burnier, Michel: 4 articles (12/2013 - 10/2007)|
|4.||Gerlach, Raquel F: 4 articles (01/2011 - 01/2006)|
|5.||Tanus-Santos, Jose E: 4 articles (01/2011 - 01/2006)|
|6.||Mancia, Giuseppe: 3 articles (01/2016 - 01/2006)|
|7.||Rizzi, Elen: 3 articles (01/2011 - 09/2008)|
|8.||Robles, N R: 3 articles (01/2010 - 01/2004)|
|9.||Menne, Jan: 3 articles (08/2009 - 05/2006)|
|10.||Martinez, Marcio L L: 3 articles (12/2008 - 01/2006)|
|1.||Hypertension (High Blood Pressure)
07/01/1999 - "Animal models of hypertension have shown lercanidipine to be potent, with a slow rate of onset and long lasting action and to have minimal or no effects on cardiac contractility. "
01/01/2015 - "Although the overall short follow-up of the present study should be taken into account, lercanidipine is an effective and safe treatment option for BP control in adult patients with mild-to-moderate primary hypertension."
11/01/2001 - "Lercanidipine has been shown to be effective in a wide range of hypertensive patients, including mild-to-moderate hypertension, severe hypertension, the elderly, and those with isolated systolic hypertension. "
11/01/2001 - "Lercanidipine is a novel DHP CCB effective for the treatment of mild-to-moderate hypertension. "
11/01/2000 - "Lercanidipine is effective in the treatment of elderly patients (aged 60 to 85 years) with mild to moderate essential hypertension and in those with isolated systolic hypertension. "
09/01/2002 - "In conclusion, lercanidipine is effective in reducing ischemia in patients with stable effort angina. "
11/01/2004 - "In conclusion, lercanidipine is safe and effective in reducing ischemia in patients with stable effort angina without any deterioration of cardiac function."
05/01/2011 - "Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP."
06/01/2001 - "This activity of lercanidipine on small-sized intracerebral arteries might represent an interesting property for the treatment of hypertensive brain damage with concomitant ischemia."
03/01/2003 - "High-dose lercanidipine had beneficial effects on coronary dysfunctions: at month 4 of the treatment period, reactive hyperemia to short duration ischemia was improved, as was the endothelium-dependent vasodilator response (acetylcholine=68 %+/-16 % vs 11 %+/-5 % in untreated CM hamsters, P<0.05) and endothelium-independent vasodilator response (sodium nitroprusside=36 %+/-5 % vs 22 %+/-12 % in untreated CM hamsters, P<0.05). "
10/01/2013 - "Lercanidipine produced a significant reduction in the inflammatory paw edema at all doses and at all intervals (P < 0.001). "
08/01/2009 - "Study participants were less likely to withdraw from the RCTs because of peripheral edema (RR = 0.24 [95% CI, 0.12-0.47]) or any adverse event (RR = 0.51 [95% CI, 0.33-0.77]) when treated with lercanidipine rather than a drug from the first generation, but not when treated with lercanidipine rather than second-generation drugs. "
10/01/2013 - "The percentage of reduction in edema was found to be proportionate to the doses of lercanidipine. "
08/01/2009 - "Another alternative to lower the incidence of edema is to use CCBs of the third generation such as lercanidipine. "
03/01/2007 - "What distinguishes lercanidipine from other members of the DHP class is its lower incidence of adverse effects, particularly edema. "
01/01/2006 - "We examined whether lercanidipine produces antioxidant effects and reduces MMP-9 activity in hypertensive patients in a placebo-controlled, crossover, single-blinded design study including 18 healthy volunteers (control group), and 14 hypertensive patients without (N = 7) or with (N = 7) diabetes mellitus. "
07/01/2002 - "These data indicate that lercanidipine is effective in lowering high blood pressure in hypertensive patients with type II diabetes mellitus and does not exert negative effects on glucose homeostasis."
07/01/2002 - "This study evaluates the effects of lercanidipine antihypertensive treatment on glucose homeostasis in patients with type II diabetes mellitus with mild to moderate hypertension. "
01/01/1998 - "In particular, studies performed so far have shown that lercanidipine does not exert a dangerous reflex tachycardia."
09/13/2006 - "Lercanidipine produces less reflex tachycardia and peripheral oedema. "
01/01/1998 - "Lercanidipine is a recently introduced example of a lipophilic and vasoselective dihydropyridine CA. It is an effective vasodilator/antihypertensive drug, with a slow onset and long duration of action, which is associated with neither reflex tachycardia nor cardiodepressant activity. "
01/01/2008 - "In contrast to first-generation dihydropyridines, lercanidipine does not induce reflex tachycardia and induces peripheral edema with a lower incidence. "
07/01/1999 - "Lercanidipine is a recently introduced example of a lipophilic and vasoselective dihydropyridine calcium antagonist which is an effective antihypertensive drug with a slow onset and long duration of action; it is associated neither with reflex tachycardia nor cardio-depressant activity."
|7.||Calcium Channel Blockers (Blockers, Calcium Channel)
|1.||Surgical Instruments (Clip)